Topical ivermectin vs topical metronidazole: Proportion of participants with adverse event
- Population
- Participants with rosacea
- Intervention
- Topical ivermectin
- Comparison
- topical metronidazole
- Outcome
- Proportion of participants with adverse event
Topical ivermectin showed no clear difference in proportion of participants with adverse event compared with topical metronidazole (moderate certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Topical ivermectin vs topical metronidazole Proportion of participants with adverse event · Participants with rosacea Topical ivermectin showed no clear difference in proportion of participants with adverse event compared with topical metronidazole (moderate certainty). Interventions for rosacea (2015) · Cochrane Headline outcomes only | RR 2.28 [0.71, 7.35] | 1 study · 962 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for rosacea 2015 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Topical ivermectin vs placebo · Participants with rosacea · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.